

eCompendium

30TH ECCMID

(EUROPEAN CONGRESS OF CLINICAL
MICROBIOLOGY AND INFECTIOUS DISEASES)

The posters and presentations listed were originally planned for presentation in Paris, France; April 18-21, 2020.

Copies of files obtained through links contained in this compendium are for personal use only and may not be reproduced without written permission of the authors. This compilation of poster links is intended as an educational resource and is for the exchange of scientific data to clinical investigators and health care professionals.

RECARBRIO

Gram Negative

ZERBAXA

Gram Negative

SIVEXTRO

Gram Positive

NOXAFIL





Antifungals



Gram Negative





Title/Authors	Access Presentation
<p>RESTORE-IMI 2: Randomized, Double-Blind, Phase 3 Trial Comparing Efficacy and Safety of Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ) in Adult Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP)</p> <p>Titov I, Wunderink R, Roquilly A, Rodriguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Kartsonis NA, Butterson JR, Paschke A, Chen LF</p>	<p>Poster Recording</p>
<p>Population Pharmacokinetic/Pharmacodynamic Assessment of a Clinical Imipenem/Cilastatin and Relebactam Dose in Patients With Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia</p> <p>Patel M, Patel P, Daryani NM, Copalu W, Kulkarni P, Hilbert DW, Young K, Rizk ML</p>	<p>Poster Recording</p>
<p>Outcomes in Ventilated Patients With Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated With Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ): Subgroup Analysis of the RESTORE-IMI 2 Randomized, Controlled Trial</p> <p>Roquilly A, Titov I, Rodriguez Gonzalez D, David-Wang A, Wunderink R, Boucher HW, Kaye KS, Losada MC, Du J, Mahoney KA, Patel M, Brown ML, Butterson JR, Paschke A, Chen LF</p>	<p>Poster</p>
<p>Baseline Microbiology, Susceptibility, and Molecular Characterization in a Recent Randomized Controlled Trial (RESTORE-IMI 2) Comparing Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ) for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP)</p> <p>Young K, David-Wang A, Roquilly A, Rodriguez Gonzalez D, Wunderink RG, Titov I, Hackel M, Kazmierczak K, Wise M, Maniar A, Hilbert DW, Losada MC, Du J, Brown ML, Paschke A, Chen LF</p>	<p>Poster</p>

**Gram Negative**

Title/Authors	Access Presentation
Imipenem/Relebactam Pharmacokinetic/Pharmacodynamic Analyses From an In Vivo Neutropenic Mouse Delayed Lung Infection Model Daryani N, Patel M, Flattery A, Young K, Rizk ML	
Imipenem/Relebactam Pharmacokinetic/Pharmacodynamic Analyses From an In Vivo Neutropenic Murine Thigh Infection Model Patel M, Daryani NM, Feng H-P, Hilbert DW, Melchers MJ, Mavridou E, Young K, Rizk ML	
Treatment Patterns and Healthcare Resource Use Among Hospitalized Adults With Carbapenem Non-susceptible Gram-Negative Infections in a Large US Electronic Health Record Database Dillon R, Burton T, Anderson A, Seare J, McCann E	
A Systematic Literature Review of the Efficacy and Tolerability of Polymyxins in Resistant Gram-Negative Infections Dillon R, Colosia A, Khan S, Masaquel C, McCann E	







Gram Negative

Title/Authors	Access Presentation
<p>Real-World Treatment Patterns Observed in Patients With Carbapenem-Resistant Gram-Negative Infections in Italian Hospitals</p> <p>Durante Mangoni E, Mastroianni C, Viale P, Bassetti M, Citton R, Fenoll R, Roset M, McCann E</p>	
<p>Outcomes and Predictors of Outcomes of Serious Infections Attributable to Carbapenem-Resistant Gram-Negative Pathogens in Southern European Hospitals</p> <p>Georgopoulos D, Durante Mangoni E, Mastroianni C, Viale P, Arnáiz de las Revillas F, Bassetti M, Ferrer R, Giamarellou-Bourboulis E, Maseda E, Salavert M, Malachias S, Bou Arevalo G, Kyriakoudi A, Tsolaki V, Lopez D, Gómez-Ulloa D, Lara N, McCann E</p>	
<p>Real-World Treatment of Patients Diagnosed With Serious Infections Due to Carbapenem-Resistant Gram-Negative Pathogens in Greek Hospitals</p> <p>Georgopoulos D, Safarika A, Ischaki E, Filiou E, Mantzarlis K, Athanasopoulos D, Fenoll R, Sánchez E, McCann E</p>	
<p>Resource Utilisation Associated With Infections Attributable to Carbapenem-Resistant Gram-Negative Pathogens in Southern European Hospitals</p> <p>Durante Mangoni E, Georgopoulos D, Fernández-Martínez M, Mastroianni C, Viale P, Bassetti M, Ferrer R, Giamarellou-Bourboulis E, Maseda E, Salavert M, Perivoliotis E, Bou Arevalo G, Koutsoukou A, Mantzarlis K, Lozano V, Gómez-Ulloa D, Roset M, McCann E</p>	



Gram Negative

Title/Authors	Access Presentation
<p>Clinical Management of Serious Infections Attributable to Carbapenem-Resistant Gram-Negative Pathogens in Spanish Hospitals</p> <p>Ferrer R, Fariñas MC, Bou G, Maseda E, Salavert M, Gómez-Ulloa D, Fenoll R, Sánchez E, Díaz-Regañón J, McCann E</p>	
<p>Retrospective Analysis of the In Vitro Activity of Imipenem/Relebactam Against KPC-Encoding Enterobacterales</p> <p>Young K, Hilbert D, Motyl M, Wise M, Kazmierczak K</p>	
<p>In Vitro Activity of Imipenem/Relebactam Against Non-Morganellaceae Enterobacterales, <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> Isolates From Patients With Respiratory Tract Infections in the United States: SMART 2016-2018</p> <p>Kazmierczak K, DePestel D, Young K, Motyl M, Sahm D</p>	
<p>In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Organisms Collected Globally From Patients With Different Infection Types: SMART 2018</p> <p>Lob S, Kazmierczak K, Young K, Motyl M, Sahm D</p>	








Gram Negative

Title/Authors	Access Presentation
<p>In Vitro Activity of Imipenem/Relebactam Against <i>Pseudomonas aeruginosa</i> Isolates Collected From Patients in Europe: SMART 2018</p> <p>Kothari N, Hawser S, Lob S, Kazmierczak K, González-Del Vecchio M, Young K, Moise P, Motyl M, Sahm D</p>	
<p>Activity of Imipenem/Relebactam Against Non-Morganellaceae Enterobacterales and <i>Pseudomonas aeruginosa</i> Isolates From 6 Countries in Western Europe: SMART 2016-2018</p> <p>Kothari N, Hawser S, Lob S, Kazmierczak K, González-Del Vecchio M, Young K, Motyl M, Sahm D</p>	
<p>In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Organisms Collected From Patients in Colombia: SMART 2015-2018</p> <p>Lob S, Kazmierczak K, Pavia J, Young K, Motyl M, Sahm D</p>	
<p>Activity of Imipenem-Relebactam Against Enterobacterales and <i>Pseudomonas aeruginosa</i> Isolates Collected in Latin America and Brazil From 2017-2018: Results From the Study for Monitoring Antimicrobial Resistance Trends (SMART)</p> <p>Gales AC, Beirão EM, Francisco Tuon F, da Silva Rodrigues S, Klain de Andrade T, Brandão Serra F, Della Negra de Paula M, Bueno Polis TJ</p>	







Gram Negative

Title/Authors	Access Presentation
<p>Emergence of Non-susceptibility Among Gram-Negative Respiratory Pathogens From a Phase 3 Clinical Trial for Treatment of Nosocomial Pneumonia (ASPECT-NP)</p> <p>Motyl M, Castanheira M, Johnson MG, Yu B, Huntington JA, Carmelitano P, Bruno C, De Anda C, Rhee EG</p>	<p>   Poster Recording </p>
<p>Exposure-Response Analyses to Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Patients With Hospital-Acquired Pneumonia (HAP)/Ventilator-Associated Pneumonia (VAP) in ASPECT-NP</p> <p>Gao W, Passare J, Patel YT, Zhang Z, Lin G, Fiedler-Kelly J, Bruno CJ, Rhee E, De Anda C, Feng H-P</p>	<p></p>
<p>Probability of Target Attainment Analyses Inform Ceftolozane/Tazobactam Dosing Regimens in Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Patients With End-Stage Renal Disease on Intermittent Hemodialysis</p> <p>Feng H-P, Patel Y, Zhang Z, Fiedler-Kelly J, Bruno C, Rhee E, De Anda C, Wei G</p>	<p></p>
<p>Ceftolozane/Tazobactam Probability of Target Attainment in Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Patients</p> <p>Zhang Z, Patel YT, Feng H-P, Johnson MG, Fiedler-Kelly J, Bruno CJ, Rhee E, De Anda C, Gao W</p>	<p></p>







Gram Negative

Title/Authors	Access Presentation
<p>Comparison of Hospital Resource Utilization Among Patients Who Received Either Ceftolozane/Tazobactam or Meropenem in ASPECT-NP: A Randomised, Controlled, Double-Blind Study of Adult Patients With Ventilated Nosocomial Pneumonia</p> <p>Puzniak L, Lodise T, Yang J, Dillon R, Kollef M</p>	
<p>Comparing the Financial Burden of Hospitalized Patients Within the Same Diagnosis Related Groups With and Without an Infection: A Multi-center Evaluation in the USA</p> <p>Yu K, Becton VG, Puzniak L, Srinivasan A</p>	
<p>Comparative Effectiveness of Ceftolozane/Tazobactam Versus Aminoglycosides or Polymyxins in Multi-drug Resistant <i>Pseudomonas aeruginosa</i> Infections</p> <p>Caffrey AR, Bodo E, Lopes V, Puzniak LA, LaPlante KL</p>	
<p>In Vitro Activity of Ceftolozane/Tazobactam and Comparators Against <i>Pseudomonas aeruginosa</i> Isolates Collected in the United States: SMART 2018</p> <p>Kazmierczak K, Young K, Motyl M, Sahm D</p>	



Gram Negative

Title/Authors	Access Presentation
<p>Evaluation of Ceftolozane/Tazobactam Disk Diffusion Testing of <i>Pseudomonas aeruginosa</i> in a Multi-centre UK Study</p> <p>Wootton M, Diggle J, Planche T, Monahan I, Alvarez-Buylla A, Allen M, Manu E</p>	
<p>Whole Genome Sequencing of <i>Pseudomonas aeruginosa</i> Isolates From Across the United Kingdom: Population Structure and Molecular Predictors of Resistance</p> <p>Planche T, Witney AA, Alvarez-Buylla A, Allen M, Manu E, Monahan I, Wootton M, and the INVICTUS study group</p>	
<p>Analysis of Resistance Mechanism Affecting Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Isolates Using Whole Genome Sequencing (STEP Study)</p> <p>Hernández-García M, García-Castillo M, García-Fernández S, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Silva T, Chaves C, Pássaro L, Paixão L, Cantón R, and the STEP study group</p>	
<p>Confronting Ceftolozane/Tazobactam Susceptibility in Multi-drug Resistant Enterobacterales Isolates and Whole Genome Sequencing Results (STEP Study)</p> <p>Hernández-García M, García-Fernández S, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Silva T, Chaves C, Pássaro L, Paixão L, Cantón R, and the STEP study group</p>	

Gram Negative

Title/Authors	Access Presentation
Characterization of Ceftolozane/Tazobactam Resistance Among Enterobacterales and <i>Pseudomonas aeruginosa</i> Isolates Recovered During the SUPERIOR Study Using Whole Genome Sequencing Hernández-García M, García-Fernández S, García-Castillo M, López-Mendoza D, Díaz-Regañón J, Cantón R, and the SUPERIOR study group	
In-Vitro Activity of Ceftolozane/Tazobactam and Comparators Against Beta-Lactam Resistant Pathogens Isolates Collected From Patients With Urinary Tract, Intra-abdominal and Lower Respiratory Infections in Lebanon and Jordan: SMART Study Data 2016-2017 Hajj A, Tarek Itani T, Hayajneh W, Hakimé N, Mallah M, Maalouf J, Alsamarneh R, Motyl M, Sahm D, Alekseeva I, Sarkis DK	




Gram Positive

Title/Authors	Access Presentation
Evaluation of Tedizolid and Comparators Activity Against Gram Positive Bacterial Isolates Causing Skin and Skin Structure Infections From Paediatric Patients in Europe and Surrounding Countries (2015-2019) Carvalhaes CG, Sader HS, Streit JM, Flamm RK, Mendes RE	
Tedizolid Activity Against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019) Carvalhaes CG, Sader HS, Streit JM, Flamm RK, Mendes RE	



Antifungals

Title/Authors	Access Presentation
<p>Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis</p> <p>Maertens JT, Rahav G, Lee DG, de León-Garduno AP, Ramírez Sánchez IC, Klimko N, Haider S, Vélez JD, Raad I, Koh L-P, Zhou J, Ben-Ami R, Motyl M, Han S, Grandhi A, Waskin H</p>	<p>   Poster Recording </p>
<p>Posaconazole Therapeutic Drug Monitoring in High Risk Hematology Patients Receiving Antifungal Prophylaxis (SAPHIR Study)</p> <p>Padoin C, Gangneux J-P, Michalet M, Saillio E, Kumichel A, Peffault de la Tour R, Ceballos P, Gastinne T, Pigneux A</p>	<p></p>
<p>The Clinical and Economic Burden of Mucormycosis in Japan</p> <p>Ueno R, Nishimura S, Fujimoto G, Ainiwaer D, Kim S-W</p>	<p></p>